Results 21 to 30 of about 194,026 (392)

Adverse Effects Associated with Proton Pump Inhibitor Use

Cureus, 2021
Proton pump inhibitors (PPIs) marked a before and after in the management of gastric acid‐related disorders since their introduction to the market in 1989.
Marcel Yibirin, Diana De Oliveira, Roberto J. Valera, Andrea E Plitt, S. Lutgen   +4 more
semanticscholar   +1 more source

Association of proton‐pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta‐analyses of cohort studies and randomised controlled trials

British Journal of Clinical Pharmacology, 2021
The aim was to perform an umbrella review to summarise the existing evidence on proton‐pump inhibitor (PPI) use and adverse outcomes and to grade the certainty of evidence.
S. Veettil, Saranrat Sadoyu, E. Bald, V. Chandran, Scott Khuu, P. Pitak, Y. Lee, A. Nair, P. Antony, A. Ford, N. Chaiyakunapruk   +10 more
semanticscholar   +1 more source

Omeprazole-induced and pantoprazole-induced asymptomatic hyponatremia: a case report

Journal of Medical Case Reports, 2020
Background Hyponatremia is the most common electrolyte disorder. Thiazides, antidepressants, antipsychotic drugs, and antiepileptic drugs are well-known causes of hyponatremia. Proton pump inhibitor use is a rare cause of hyponatremia and, when reported,
Isabel J. B. van der Zalm, Tom J. M. Tobé, Susan J. J. Logtenberg   +2 more
doaj   +1 more source

Overprescribing proton pump inhibitors [PDF]

BMJ, 2008
Proton pump inhibitors are one of the most frequently prescribed classes of drug in the world because they combine a high level of efficacy with low toxicity. In 2006, expenditure on these drugs was £425m (€595m; $872m) in England1 and £7bn globally.2 Yet studies consistently show that proton pump inhibitors are being overprescribed worldwide in both ...
Ian, Forgacs, Aathavan, Loganayagam
openaire   +2 more sources

Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer

JAMA Network Open, 2021
This cross-sectional study evaluates the prevalence of proton pump inhibitor use among patients with cancer at 4 French comprehensive cancer centers.
J. Raoul, C. Guérin-Charbonnel, J. Edeline, V. Simmet, M. Gilabert, J. Frenel   +5 more
semanticscholar   +1 more source

Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. [PDF]

, 2012
Introduction Emerging epidemiological evidence suggests that proton pump inhibitor (PPI) acid-suppression therapy is associated with an increased risk of Clostridium difficile infection (CDI).
A Deshpande, A Liberati, A Niklasson, Abdur Rahman Khan, Abed AlLehibi, Alex J. Sutton, Aref A. Bin Abdulhak, AZ Mat Saad, BT Batuwitage, C Bavishi, C Cahir, CM Wilcox, CS Eom, CS Kwok, D Ahrens, DF Stroup, DL Bhatt, DO Lowe, F Sierra, Faisal A. Alasmari, GH Guyatt, Imad M. Tleyjeh, J Johnstone, J Leonard, J Theisen, J Thorens, J Zhang, JL Peters, JM Boyce, JS Bajaj, KH Wilson, Larry M. Baddour, LC McDonald, LK Archibald, M Charlot, M Egger, Markus M. Heimesaat, MD Howell, MD Redelings, MM Nerandzic, Mohamad Al Tannir, Muhammad Riaz, Musa A. Garbati, Mushabab AlGhamdi, Patricia J. Erwin, PK Kutty, PS Yachimski, R DerSimonian, R Scagliarini, RL Jump, S Dial, S Janarthanan, S Jayatilaka, S Linney, S Schneeweiss, SG Moreno, SG Moreno, Talal Ibrahim, WR Jarvis   +58 more
core   +6 more sources

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing

Clinical pharmacology and therapy, 2020
Proton pump inhibitors (PPIs) are widely used for acid suppression in the treatment and prevention of many conditions, including gastroesophageal reflux disease, gastric and duodenal ulcers, erosive esophagitis, Helicobacter pylori infection, and ...
J. Lima, Cameron D Thomas, Julia M. Barbarino, Z. Desta, S. V. Van Driest, Nihal El Rouby, Julie A. Johnson, L. Cavallari, V. Shakhnovich, D. L. Thacker, S. Scott, M. Schwab, C. Uppugunduri, Christine M. Formea, J. Franciosi, K. Sangkuhl, A. Gaedigk, T. Klein, Roseann S. Gammal, T. Furuta   +19 more
semanticscholar   +1 more source

Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis

Cost Effectiveness and Resource Allocation, 2021
Background To estimate the cost -utility of imrecoxib compared with diclofenac, as well as the addition of a proton pump inhibitor to both two treatment strategies, for patients with osteoarthritis, from a Chinese healthcare perspective. Methods A Markov
Xueshan Sun, Xuemei Zhen, Xiaoqian Hu, Yuanyuan Li, ShuYan Gu, Yuxuan Gu, Zixuan Zhao, Wei Yang, Hengjin Dong   +8 more
doaj   +1 more source

Proton pump inhibitor deprescription: A rapid review [PDF]

Brazilian Journal of Pharmaceutical Sciences, 2022
Proton pump inhibitors (PPI) are drugs that suppress gastric acid secretion. Its use, without support from scientific evidence, can contribute to polypharmacy, lead to drug interactions and, in the long term, cause serious adverse reactions.
Renata Rodriguez Imparato, Tereza Setsuko Toma   +1 more
doaj   +1 more source

Relationship Between Long-Term Proton Pump Inhibitor Use and Serum Magnesium Levels: A Cross-Sectional Study

Life and Science, 2023
Objective: The objective of this study is to determine the effect of long-term proton pump inhibitor use on serum magnesium levels Study Design: Descriptive cross-sectional study.
Fuad Ahmad Siddiqi, Wasif Anwar, Muhammad Saad Aziz, Muhammad Hammad, Abdul Rehman Arshad, Umer Naseer   +5 more
doaj   +1 more source